Last reviewed · How we verify
Carbocaine (MEPIVACAINE)
Carbocaine (generic name: MEPIVACAINE) is a Amide Local Anesthetic Small molecule drug developed by Eastman Kodak. It is currently FDA-approved (first approved 1960) for Administration of Local Anesthetic Nerve Block, Administration of Regional Anesthesia, Local anesthesia.
Mepivacaine, marketed by Eastman Kodak, is a local anesthetic nerve block agent currently facing competition from several same-class drugs, including bupivacaine, lidocaine, and prilocaine. Its key strength lies in its mechanism of action, which effectively blocks sodium channels in nerve cells to prevent pain signals, offering a reliable option for local anesthesia. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | MEPIVACAINE |
|---|---|
| Sponsor | Eastman Kodak |
| Drug class | Amide Local Anesthetic |
| Target | Sodium channel protein type 1 subunit alpha |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 1960 |
Approved indications
- Administration of Local Anesthetic Nerve Block
- Administration of Regional Anesthesia
- Local anesthesia
- Local anesthesia, by infiltration
Common side effects
- Convulsions
- Cardiac arrest
- Respiratory arrest
- Ventricular arrhythmias
- Heart block
- Hypotension
- Hypertension
- Bradycardia
- Anaphylactoid-like symptomatology
- Urticaria
- Pruritus
- Erythema
Key clinical trials
- Femoral Peri-arterial Local Anesthetic Injection Via Peri-arterial Perineural Catheter Reverses Tourniquet Associated Ischemic Hypertension (PHASE4)
- Discomfort Following Oral Biopsy Comparing Laser and Punch Biopsy (NA)
- Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction (PHASE1,PHASE2)
- Comparing Spinal Anesthesia With 1% Chloroprocaine Versus 1% Mepivacaine in Patients Undergoing Outpatient Primary Total Knee Arthroplasty (PHASE4)
- Oct Angiography Changes After Local Anesthesia in Cataract Surgery (NA)
- PENG Block + LIA For Endoprosthesis Surgery With Anterior Approach (NA)
- A Randomized Controlled Trial Evaluating Whether Pre-operative Trinase Reduces Post-operative Pain in Patients With Symptomatic Irreversible Pulpitis Compared to Placebo, Using VAS Scores and Analgesic Intake Over 48 Hours. (NA)
- Platelet-Rich Plasma Versus Home-Based Exercise for Partial-Thickness Supraspinatus Tears (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carbocaine CI brief — competitive landscape report
- Carbocaine updates RSS · CI watch RSS
- Eastman Kodak portfolio CI
Frequently asked questions about Carbocaine
What is Carbocaine?
What is Carbocaine used for?
Who makes Carbocaine?
What is the generic name of Carbocaine?
What drug class is Carbocaine in?
When was Carbocaine approved?
What development phase is Carbocaine in?
What are the side effects of Carbocaine?
What does Carbocaine target?
Related
- Drug class: All Amide Local Anesthetic drugs
- Target: All drugs targeting Sodium channel protein type 1 subunit alpha
- Manufacturer: Eastman Kodak — full pipeline
- Therapeutic area: All drugs in Pain
- Indication: Drugs for Administration of Local Anesthetic Nerve Block
- Indication: Drugs for Administration of Regional Anesthesia
- Indication: Drugs for Local anesthesia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing